COVID-19
Conditions
Keywords
COVID-19 vaccine, Ad5-nCoV
Brief summary
This is a clinical trial to evaluate the safety and immunogenicity of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses and with different adminstration routes in healthy adults aged 18 years and older.
Detailed description
A total of 168 healthy adult volunteers will be vaccinated in this clinical trial according to open, partly randomized design from the healthy adults aged 18 years and older. The safety and immunogenicity of intramuscular vaccination and mucosal vaccination of two doses of Ad5-nCoV in different administration schedules will be evaluated.
Interventions
BIOLOGICALAd5-nCoV
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Sponsors
Zhongnan Hospital
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 years and older; * Able to provide consent to participate in and having signed an Informed Consent Form (ICF); * Able and willing to complete all the scheduled study procedures during the whole study follow-up period (about 6-8 months, depending on group); * Negative result of HIV screening; * Axillary temperature ≤37.0°C. * Negative IgG and IgM antibodies against COVID-19; * Good general health status, as determined by history and physical examination.
Exclusion criteria
for the first vaccination: * Hematological examination is abnormal, or clinically significant as assessed by the study investigator (including white blood cell count, lymphocyte count, neutrophil count, eosinophil count, platelet, hemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, blood glucose and creatinine); * With oral ulcers, throat swelling and other oral diseases. * With symptoms of upper respiratory tract infection. * Personal history of seizure disorder, encephalopathy or psychosis; * Allergic history to any vaccine, or allergic to any ingredient of the Ad5-nCoV; * Any acute febrile disease or active infectious disease on the day of vaccination; * History of SARS or COVID-19; * History of COVID-19 candidate vaccine administration; * History of chronic obstructive pulmonary disease (COPD). * Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension not controlled with medication; * Serious chronic disease or in the advanced stage that cannot be controlled well， such as asthma, diabetes and thyroid disease, etc.; * Congenital or acquired angioedema; * Suffered from urticaria within 1 year before receiving the trial vaccine. * Asplenia or functional asplenia; * Platelet disorder or other bleeding disorder that may cause intramuscular injection contraindication; * Faint with needles in intramuscular administration group; * Immunosuppressive medication, anti-allergic, cytotoxic therapy, inhaled corticosteroids (excluding surface corticosteroid therapy for acute non-complicated dermatitis) in the last 6 months; * Prior administration of blood products in last 4 months; * Other vaccination(s) or investigational drugs within 1 month before study onset; * Prior administration of live attenuated vaccine within 1 month before study onset; * Prior administration of subunit or inactivated vaccine within 14 days before study onset; * Current anti-tuberculosis therapy; * Woman is pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the next 8 months; * Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of the AE in all groups | 0-7 days after each vaccination | The occurrence of AE in all groups within 0-7 days after each vaccination; |
| Seroconversion rate of the IgG antibody against SARS-CoV-2 | Day 28 after last vaccination | Seroconversion rate the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination |
| Geomean titers of the IgG antibody against SARS-CoV-2 | Day 28 after last vaccination | Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination |
| Seroconversion rate of the neutralizing antibody against SARS-CoV-2 | Day 28 after last vaccination | Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination |
| Geomean titers of the neutralizing antibody against SARS-CoV-2 | Day 28 after last vaccination | Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion rate of the IgG antibody against SARS-CoV-2 | Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination. | Seroconversion rate of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination. |
| Geomean titers of the neutralizing antibody against SARS-CoV-2 | Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination. | Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination. |
| Cellular immune response by ELISpot | Day 0 and Day 14 after each vaccination | The positive rate of IFN-γ stimulated by S protein overlapping peptide library detected by ELISpot on Day 0 and Day 14 after each vaccination |
| Cellular immune response by ICS | Day 0 and Day 14 after each vaccination | The positive rate of the specific cytokines expressed by CD4+ and CD8+ T lymphocytes stimulated by S protein overlapping peptide library detected by intracellular cytokine staining on Day 0 and Day 14 after each vaccination |
| Geomean titers of the IgA antibody against SARS-CoV-2 | Day 0, 14 and 28 after each vaccination | Geomean titers of the IgA antibody against SARS-CoV-2 on Day 0, 14 and 28 after each vaccination. |
| Geomean titers of neutralizing antibody response to Ad5-vector | Day 0, 14 and 28 after each vaccination. | Geomean titers of neutralizing antibody response to Ad5-vector on Day 0, 14 and 28 after each vaccination. |
| Seroconversion rate of the neutralizing antibody against SARS-CoV-2 | Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination. | Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 0, Day14, Day 28 or Day 56 after first vaccination and on day 14, day 28 and day168 after last vaccination. |
| Incidence of the AE in all groups | 0-30 minutes, 0-28 days after each vaccination | The occurrence of AE in all groups within 0-30 minutes and 0-28 days after each vaccination. |
| Incidence of Serious adverse events (SAE) in all groups | 6 months after the final vaccination | The occurrence of Serious adverse events (SAE) in all groups within 6 months after the final vaccination. |
| Geomean titers of the IgG antibody against SARS-CoV-2 | Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination. | Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination. |
Countries
China
Outcome results
None listed